Chris Elliott Fund Comments on Support of Project Violet Initiatives
Seattle, WA (PRWEB) September 05, 2013 -- On August 29th, Dellann Elliott Mydland of the Chris Elliott Fund released a statement on their support of the initiatives of Project Violet:
"In the 12 years that Chris Elliott Fund has provided patient support to the brain cancer community, we’ve seen how vital the development of new and innovative treatments is to patients diagnosed with brain cancer. Supporting brain cancer research is and will continue to be huge part of our mission and that is why we support Project Violet."
"We identify this as a once in a lifetime opportunity to finally discover a treatment for brain cancer and save lives. We understand that research programs require the need for resources that cannot be raised by any single individual. And we simply cannot allow such an important research program to end due to financial constraint."
"Through Project Violet, the public has a rare opportunity to not only fund research that could help brain tumor patients but to have a seat at the table and share in the triumph and challenges of science from initial research stages through to FDA approval. Chris Elliott Fund in, support of Project Violet, is asking any of those to help."
"We encourage all to join us in supporting Project Violet by watching Dr. Olson’s recent TEDxSeattle talk video at http://www.projectviolet.org, each video view will result in a $10 donation (of up to $50,000) made by the Washington Research Foundation (WRF), an organization that supports ground breaking research to Project Violet."
"We encourage you to take this opportunity to play a role in finding a cure and help provide hope to the many people inflicted by this devastating disease." - Dellann Elliott Mydland, Founder and President Chris Elliott Fund
About Project Violet:
Project Violet is a collaborative project between researchers from the University of Washington. Researchers Jim Olson, M.D., PhD Patrick Paddison, M.D. have discovered two new drug targets for glioblastoma – BUB1B and PHF5a. In a recent statement, Dr. Olson stated, “these targets, when knocked down, kill glioblastoma cells but not normal brain cells and we think that an effective drug against either would benefit brain cancer patient.”
About the Chris Elliott Fund:
The Chris Elliott Fund (CEF) is a brain cancer and brain tumor patient advocacy organization and national 501(c)(3) non-profit with corporate offices in Seattle, Washington. Established in 2002, Chris Elliott Fund’s mission is to end brain cancer by expanding patient access to specialists, advanced treatments and comprehensive support programs. The organization and its advocates directly serves 400+ patients and caregivers every month free of charge. CEF is a member of the Society for Neurooncologists, American Association of Neuroscience Nurses, American Cancer Association for Cancer Research, Washington Biosciences Association, among others. If we can help, please contact us at WeCare(at)EndBrainCancer(dot)com.
Rachel Tougher, Chris Elliott Fund, http://www.chriselliottfund.org, +1 (253) 651-5331, [email protected]
Share this article